Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Nitrogen containing other than solely as a nitrogen in an...
Patent
1996-02-09
1998-12-01
Cook, Rebecca
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Nitrogen containing other than solely as a nitrogen in an...
A61K 31135
Patent
active
058440038
ABSTRACT:
The present invention relates to the use of deprenyl compounds to rescue damaged nerve cells in a patient and to kits containing deprenyl compounds useful for rescuing damaged nerve cells in a patient.
REFERENCES:
patent: 4861800 (1989-08-01), Buyske
patent: 5444095 (1995-08-01), Tatton et al.
Tatton et al, J. of Neuroscience Research, 30: 666-672 (1991).
Tatton et al, Can. J. Neurol. Sci., 1992; 19:124-133.
Birkmayer, W. et al.; (1985) "Increased Life Expectancy Resulting from Addition of L-Deprenyl to Madopar.RTM. Treatment in Parkinson's Disease: A Longterm Study"; J. Neural Transmission; 64; pp. 113-127.
Finnegan, Kevin T. et al.; (1990) "Protection against DSP-4-induced neurotoxicity by deprenyl is not related to its inhibition of MAO B"; Euro. J. Pharmacol.; 184(1); abstract of pp. 119-126.
Greenwood, Carol E. et al.; (1991) "Increased Dopamine Synthesis in Aging Substantia Nigra Neurons"; Neurobiology of Aging; vol. 12; pp. 557-565.
Heikkila et al; (1985) "Dopaminergic Neurotoxicity of 1-Methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP) in the Mouse: Relationships Between Monoamine Oxidase, MPTP Metabolism and Neurotoxicity"; Life Sciences; 36; pp. 231-236.
Jonakait, G. Miller et al.; (1988) "Development of serotonin, substance P and thyrotrophin-releasing hormone in mouse medullary raphe grown in organotypic tissue culture: developmental regulation by serotonin"; Brain Research, 473; pp. 336-343.
The Merck Index; (1983) 10th edition, Windholz, M. (Ed.), abstract 2893, p. 423, abstract 6988, p. 1023, abstract 1983; p. 282.
Rinne; (1991) "Nigral degeneration in Parkinson's disease in relation to clinical features"; Acta Neurol Scand.; 84: Supp. 136; pp. 87-90.
Rinne et al; (1991) "Selegine (deprenyl) treatment and death of nigral neurons in Parkinson's disease"; Neurology; 41; pp. 859-861.
Seniuk et al; (1990) "Dose-dependent destruction of the coeruleus-cortical and nigral-striatal projections by MPTP"; Brain Res.; 527(1); pp. 7-20.
Tatton et al.; (1992); "Interactions Between MPTP-Induced and Age-Related Neuronal Death in a Murine Model of Parkinson's Disease"; Can. J. Neurological Sciences; 19(1) (Supp.); pp. 124-133.
Tatton, W.G. and Greenwood, C.E., (1991); "Rescue of Dying Neurons: A New Action for Deprenyl in MPTP Parkinsonism"; Journal of Neuroscience Research; 30; pp. 666-672.
Tatton et al.; (1991) "Different Rates of Age-Related Loss For Four Murine Monoaminergic Neuronal Populations"; Neurobiol. of Aging; 12; pp. 543-556.
Tatton et al; (1991) "Transmitter synthesis increases in substantia nigra neurons of the aged mouse"; Neuroscience Letters; 131; pp. 179-182.
Tatton et al; (1990); "MPTP produces reversible disappearance of tyrosine hydroxylase-containing retinal amacrine cells"; Brain Res.; 527(1); pp. 21-31.
Timar, Julia; (1989) "Recovery of Mao-B Enzyme Activity After (-)Deprenyl (Selegiline) Pretreatment, Measured In Vivo"; Acta Physiologica Hungarica; vol. 74(3-4); pp. 259-266.
Torok, Tamas L. et al; (1987) "Transmitter releasing action of selegiline ((-)-deprenyl) from peripheral sympathetic nerves under different experimental conditions"; J. Pharm. Pharmacol.; 39(10); abstract of pp. 797-802, pp. 48 of Chemical Abstracts.
Zsilla, Gabriella et al.; (1984) "Neurochemical evidences for facilitation of dopaminergic function in rat brain by repeated doses of (-) deprenyl"; Dev. Neurosci. (Amsterdam); 17 (Regular Transm. Funct.: Basic Clin. Aspects); abstract of pp. 345-348; pp. 64 of Chemical Abstracts.
Zsilla, Gabriella et al.; (1986) "The Effect of Repeated Doses of (-) Deprenyl On The Dynamics of Monoaminergic Transmission. Comparison With Clorgyline"; Pol. J. Pharmacol. Pharm.; 38; pp. 57-67.
Zsilla, Gabriella et al.; (1983) "(-)-Deprenyl A Selective Mao `B` .beta.-Adrenergic Receptor Function"; European Journal of Pharmacology; 89; pp. 111-117.
Zsilla, G. and Knoll, J.; (1982) "The Action of (-)Deprenyl on Monoamine Turnover Rate in Rat Brain"; Typical and Atypical Antidepressants: Molecular Mechanisms; pp. 211-217.
Heinonen, E.H. et al;. (1993) "Desmethylselegiline, a metabolite of selegiline, is an irreversible inhibitor of MAO-B in human subjects"; Neurology; vol. 43(4); pp. A156.
Knoll, J. et al.; (1992) "(-)Deprenyl and (-)parafluorodeprenyl treatment prevents age-related pigment changes in the substania nigra"; Mech. Ageing Dev;; vol. 63(2); pp. 157-163.
Magyar, K.; (1994) "Behaviour of (-)deprenyl and its analogues" Journal of Neural Transmission; vol. 41; pp. 167-175.
Nickel B. et al.; (1990) "Effect of selegiline and desmethyl-selegiline on cortical electric activity in rats" Journal of Neural Transmission; Suppl. 32; pp. 139-144.
Rao, T.S., et al.; (1987) "N, N-Dipropargyl-2-Phenylethylamine, a potential prodrug of 2-Phenylethlamine: neurochemical and neuropharmalogical studies in rat" Brain Res. Bull.; vol. 19(1); pp. 47-55.
Greenwood Carol E.
Tatton William G.
Cook Rebecca
Hanley Elizabeth A.
Innovations Foundation
Russett Mark D.
LandOfFree
Use of deprenyl compounds to maintain, prevent loss, or recover does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of deprenyl compounds to maintain, prevent loss, or recover , we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of deprenyl compounds to maintain, prevent loss, or recover will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2396124